Velabs Therapeutics announces strategic partnership with alytas therapeutics to develop a novel immune-based therapy for obesity Velabs Therapeutics announces strategic partnership with alytas therapeutics to develop a novel immune-based therapy for obesity September 3, 2019 General Read more
Velabs Therapeutics enters into a screening cooperation with Chiome Bioscience in the field of GPCR-specific functional antibody screening after successful feasibility study Velabs Therapeutics enters into a screening cooperation with Chiome Bioscience in the field of GPCR-specific functional antibody screening after successful feasibility study August 27, 2019 General Read more
Understanding molecular mechanisms of ageing Understanding molecular mechanisms of ageing August 15, 2019 General Read more
Velabs Therapeutics Announces €3 Million Series B Financing to Advance its Functional Antibody Screening Programme Velabs Therapeutics Announces €3 Million Series B Financing to Advance its Functional Antibody Screening Programme June 28, 2019 General Read more
EMBL spin-off Velabs Therapeutics to cooperate with Chiome Bioscience in the field of GPCR-specific functional antibody screening EMBL spin-off Velabs Therapeutics to cooperate with Chiome Bioscience in the field of GPCR-specific functional antibody screening April 24, 2019 General Read more
Prioritising cancer drug targets using CRISPR Prioritising cancer drug targets using CRISPR April 11, 2019 General Read more
